Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8507977 | 1.00 | TSHR (0.56) | TSHRCYP2C9PDE4AALDH1A1FFAR3 | |
| SCHEMBL9965103 | 0.84 | TSHR (0.56) | TSHRCYP2C9PDE4AALDH1A1FFAR3 | |
| SCHEMBL9463777 | 0.84 | CYP2C9 (0.46) | TSHRCYP2C9ALDH1A1FFAR3TDP1 | |
| Mucic Acid SCHEMBL27648912 | 0.82 | FFAR3 (0.53) | TSHRCYP2C9PDE4AALDH1A1FFAR3 | |
| Mucic Acid SCHEMBL6672352 | 0.81 | PDE4A (0.56) | TSHRCYP2C9PDE4AALDH1A1FFAR3 | |
| SCHEMBL16620971 | 0.80 | TSHR (0.34) | TSHRCYP2C9PDE4AALDH1A1FFAR3 | |
| SCHEMBL28137936 | 0.80 | TSHR (0.34) | TSHRCYP2C9PDE4AALDH1A1FFAR3 | |
| SCHEMBL17545491 | 0.80 | TDP1 (0.36) | TSHRCYP2C9PDE4AALDH1A1FFAR3 | |
| Mucic Acid SCHEMBL3514596 | 0.78 | TSHR (0.69) | TSHRCYP2C9PDE4AALDH1A1TP53 | |
| Mucic Acid SCHEMBL17594183 | 0.78 | TSHR (0.69) | TSHRCYP2C9PDE4AALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567636-A | Anti-ethyl glucuronic acid monoclonal antibody, application and product thereof | 杭州旭科生物技术有限公司 | 2024-02-20 | — | — | CN | claimed |
| CN-114660299-A | Biomarker and kit for diagnosing or preventing liver injury and application of biomarker and kit | 中南大学 | 2022-06-24 | — | — | CN | claimed |
| CN-117807561-A | Method for acquiring substance concentration prediction model, urine substance detection method and system | 杉木(深圳)生物科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117567636-A | Anti-ethyl glucuronic acid monoclonal antibody, application and product thereof | 杭州旭科生物技术有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-114929391-A | Microfluidic systems, devices and methods | 毕速股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-114660299-A | Biomarker and kit for diagnosing or preventing liver injury and application of biomarker and kit | 中南大学 | 2022-06-24 | — | — | CN | disclosed |
| US-20130059807-A1 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | SATIOGEN PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130034536-A1 | Bile Acid Recycling Inhibitors for Treatment of Pancreatitis | Lumena Pharmaceuticals, Inc. (US) | 2013-02-07 | — | — | US | disclosed |
| US-20120157399-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SATIOGEN PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20100130472-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SATIOGEN PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157399-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SLC10A1, SLC10A2, ABCB11 | TSHR 1089/4885CYP2C9 1684/4885PDE4A 1107/4885 |
| US-20130059807-A1 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | SLC10A2, GPR119, GPBAR1 | TSHR 968/4885CYP2C9 3391/4885PDE4A 2820/4885 |
| US-20130034536-A1 | Bile Acid Recycling Inhibitors for Treatment of Pancreatitis | SLC10A2, SLC10A1, NR1H4 | TSHR 297/4885CYP2C9 4523/4885PDE4A 453/4885 |
| US-20100130472-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SLC10A1, SLC10A2, ABCB11 | TSHR 1089/4885CYP2C9 1684/4885PDE4A 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.